ClinicalTrials.gg
CompletedNCT04711837Updated Oct 10, 2025Results posted

Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery

A Phase 3 interventional study of HSK3486 and Propofol in Anesthesia, sponsored by Haisco-USA Pharmaceuticals, Inc.. Completed at 13 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by Haisco-USA Pharmaceuticals, Inc. (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, randomized, double-blinded, propofol-controlled, Phase 3 clinical study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in adults undergoing elective surgery.

02

Conditions studied

  • Anesthesia

Keywords

  • Anesthesia
  • Elective surgery
  • Propofol
03

In context

Lead sponsor

Haisco-USA Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects undergoing elective surgery (nonemergency, noncardiothoracic, and nonintracranial surgery anticipated to last at least 1 hour ).
  • Males or females, aged ≥18 years old, with Physical Status (ASA PS) I to IV.
  • (BMI) ≥18 kg/m2.
  • For all females of , negative pregnancy test at screening and baseline. Additionally, females of childbearing potential must agree to use (such as condom, intrauterine device [IUD], abstinence) from the time of consent until 30 days post study drug administration.
  • Capable of understanding the procedures and methods of this study, willing to sign an Form, and to complete this study in strict compliance with the study protocol.

Exclusion criteria

Exclusion Criteria:

  • to deep sedation/general anesthesia or a history of adverse reaction to sedation/general anesthesia.
  • Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subject having contraindications to propofol, opioids, and their antidotes.
  • Medical condition or evidence of increased sedation/general anesthesia risk.
  • Management risks of respiratory tract and judged by the investigator to be unsuitable for inclusion in the study.
  • Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics.
  • Laboratory parameters significantly out of range at screening.
  • Female subjects with a positive pregnancy test (serum or urine) at screening or baseline; lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).
  • Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    HSK3486

    HSK3486 for induction of general anesthesia.

    Drug: HSK3486

  • Active comparator
    Propofol

    Propofol for induction of general anesthesia.

    Drug: Propofol

Interventions

  • HSK3486 for induction of general anesthesia.

  • Propofol for induction of general anesthesia.

    Also known as: Diprivan

06

What researchers measure

Primary outcomes

  1. Number of Participants With Successful Anesthesia Induction

    The primary outcome of interest was the success rate of anesthesia induction, defined by the proportion of subjects with successful anesthesia. A subject was considered successful for anesthetic induction if the following conditions were met: induction success Modified Observer's Assessment of Awareness/Sedation Scale (MOAA/S ≤1) after administration of study drug and 1 or less top-up dose required without using any rescue drugs. Where Grade 0 is no response after trapezius squeeze, Grade 1 responds only after painful trapezius squeeze and Grade 5 is completely awake responds to name spoken in normal tone.

    Time frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes)

Secondary outcomes

  1. Subjects' NRS Pain Score

    Injection-site pain is evaluated verbally during study drug administration using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worse imaginable pain). Subjects' NRS pain score at the time of study drug administration (Day 1) and recall of pain score in PACU.

    Time frame: Up to 8 hours

  2. Proportion of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression.

    The proportion of subjects with successful induction who maintain the desired depth of anesthesia for general elective surgery, AND without significant cardiac and respiratory depression between the time of successful induction and 15 minutes post initiation of study drug administration, or up to the beginning of second tracheal intubation attempt if it is a difficult condition and not beyond 15 minutes post initiation of study drug administration.

    Time frame: 15 minutes from end of drug administration.

  3. Proportion of Subjects With Any Injection-site Pain on Numeric Rating Scale.

    The proportion of subjects with any injection-site pain at time of drug administration on the Numeric Rating Scale (NRS ≥1).

    Time frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes)

  4. Time to Successful Induction of General Anesthesia.

    Time from the end of the first administration of the study drug to MOAA/S ≤1.

    Time frame: From end of drug administration to MOAA/S ≤1 (up to 5 minutes)

Other outcomes

  1. Time to the Disappearance of Eyelash Reflex

    Time from the end of the first administration of the study drug to the disappearance of eyelash reflex.

    Time frame: From end of drug administration to disappearance of eyelash reflex (up to 5 minutes)

  2. Number of Participants That Failed to Meet Successful Induction of General Anesthesia

    Failed to meet successful induction of general anesthesia defined by the use of the Top-up Study Drug and Rescue/Remediation Drugs

    Time frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes)

07

Results

Posted May 26, 2023

Participant flow

Participant flow — Overall Study
MilestoneHSK3486Propofol
Started17085
Completed16883
Not completed22

Outcome measures

PrimaryNumber of Participants With Successful Anesthesia Induction

The primary outcome of interest was the success rate of anesthesia induction, defined by the proportion of subjects with successful anesthesia. A subject was considered successful for anesthetic induction if the following conditions were met: induction success Modified Observer's Assessment of Awareness/Sedation Scale (MOAA/S ≤1) after administration of study drug and 1 or less top-up dose required without using any rescue drugs. Where Grade 0 is no response after trapezius squeeze, Grade 1 responds only after painful trapezius squeeze and Grade 5 is completely awake responds to name spoken in normal tone.

Time frame:
From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
Reported as:
Count of participants · Participants
Number of Participants With Successful Anesthesia Induction
ParticipantsHSK3486Propofol
Number of Participants With Successful Anesthesia Induction16381
SecondarySubjects' NRS Pain Score

Injection-site pain is evaluated verbally during study drug administration using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worse imaginable pain). Subjects' NRS pain score at the time of study drug administration (Day 1) and recall of pain score in PACU.

Time frame:
Up to 8 hours
Reported as:
Count of participants · Participants
Subjects' NRS Pain Score
ParticipantsHSK3486Propofol
Proportion of NRS ≥ 1 pain score on Day 1 — Proportion of NRS ≥1 and <4 pain score2013
Proportion of NRS ≥ 1 pain score on Day 1 — Proportion of NRS ≥4 pain score1051
Proportion of NRS ≥ 1 pain score on Day 1 — Proportion of NRS = 0 Pain score13719
Proportion of NRS ≥ 1 pain score on Day 1 — Missing NRS10
Proportion of NRS ≥ 1 pain Score in PACU — Proportion of NRS ≥1 and <4 pain score2717
Proportion of NRS ≥ 1 pain Score in PACU — Proportion of NRS ≥4 pain score1939
Proportion of NRS ≥ 1 pain Score in PACU — Proportion of NRS = 0 Pain score11321
Proportion of NRS ≥ 1 pain Score in PACU — Missing NRS96
SecondaryProportion of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression.

The proportion of subjects with successful induction who maintain the desired depth of anesthesia for general elective surgery, AND without significant cardiac and respiratory depression between the time of successful induction and 15 minutes post initiation of study drug administration, or up to the beginning of second tracheal intubation attempt if it is a difficult condition and not beyond 15 minutes post initiation of study drug administration.

Time frame:
15 minutes from end of drug administration.
Reported as:
Count of participants · Participants
Proportion of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression.
ParticipantsHSK3486Propofol
Successful Induction16381
Failed Induction52
SecondaryProportion of Subjects With Any Injection-site Pain on Numeric Rating Scale.

The proportion of subjects with any injection-site pain at time of drug administration on the Numeric Rating Scale (NRS ≥1).

Time frame:
From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
Reported as:
Count of participants · Participants
Proportion of Subjects With Any Injection-site Pain on Numeric Rating Scale.
ParticipantsHSK3486Propofol
Proportion of Subjects With Any Injection-site Pain on Numeric Rating Scale.3064
SecondaryTime to Successful Induction of General Anesthesia.

Time from the end of the first administration of the study drug to MOAA/S ≤1.

Time frame:
From end of drug administration to MOAA/S ≤1 (up to 5 minutes)
Reported as:
Median · minutes
Time to Successful Induction of General Anesthesia.
minutesHSK3486Propofol
Time to Successful Induction of General Anesthesia.0.75 (0.6167 to 0.9000)0.62 (0.5167 to 0.8000)
Other pre-specifiedTime to the Disappearance of Eyelash Reflex

Time from the end of the first administration of the study drug to the disappearance of eyelash reflex.

Time frame:
From end of drug administration to disappearance of eyelash reflex (up to 5 minutes)
Reported as:
Median · minutes
Time to the Disappearance of Eyelash Reflex
minutesHSK3486Propofol
Time to the Disappearance of Eyelash Reflex0.92 (0.8333 to 1.0000)0.80 (0.7333 to 1.0000)
Other pre-specifiedNumber of Participants That Failed to Meet Successful Induction of General Anesthesia

Failed to meet successful induction of general anesthesia defined by the use of the Top-up Study Drug and Rescue/Remediation Drugs

Time frame:
From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
Reported as:
Count of participants · Participants
Number of Participants That Failed to Meet Successful Induction of General Anesthesia
ParticipantsHSK3486Propofol
Number of Participants That Failed to Meet Successful Induction of General Anesthesia52
Statistical analysis
  • HSK3486 vs Propofol · Farrington-Manning method · Risk difference (rd): -0.0057 · 95% CI -0.054 to 0.042

Adverse events

Collected over Adverse event reporting begins from the time of informed consent and ends 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HSK34860/168 (0%)0/168 (0%)47/168 (28%)
Propofol0/83 (0%)3/83 (3.6%)27/83 (32.5%)
Most frequent serious events
Most frequent serious events
EventHSK3486Propofol
Pulmonary EmbolismCardiac disorders0/1681/83
Abdominal Wall HaematomaGastrointestinal disorders0/1681/83
Femur FractureMusculoskeletal and connective tissue disorders0/1681/83
Most frequent other events
Most frequent other events
EventHSK3486Propofol
HypotensionVascular disorders47/16827/83
NauseaGastrointestinal disorders46/16827/83
Procedural PainInjury, poisoning and procedural complications32/16819/83

Baseline characteristics

Age, Customized
Age, Customized(Participants)HSK3486PropofolTotal
Age Group (Years) — ≥65271441
Age Group (Years) — <6514169210
Sex: Female, Male
Sex: Female, Male(Participants)HSK3486PropofolTotal
Female11957176
Male492675
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HSK3486PropofolTotal
Hispanic or Latino452368
Not Hispanic or Latino11858176
Unknown or Not Reported527
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HSK3486PropofolTotal
American Indian or Alaska Native000
Asian404
Native Hawaiian or Other Pacific Islander000
Black or African American361248
White12171192
More than one race202
Unknown or Not Reported505
08

Study locations

13 sites
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Lotus Clinical Research, LLC
    Pasadena, California 91105, United States
  • Phoenix Clinical Research, LLC
    Tamarac, Florida 33321, United States
  • The University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • New York City Heath and Hospitals
    New York, New York 10013, United States
  • Stony Brook University Hospital
    Stony Brook, New York 11794, United States
  • UNC Health Care System
    Chapel Hill, North Carolina 27599, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • The Ohio State University Research Foundation
    Columbus, Ohio 43210, United States
  • HD Research
    Bellaire, Texas 77401, United States
  • Plano Surgical Hospital
    Plano, Texas 75093, United States
  • Endeavor Clinical Trials, LLC
    San Antonio, Texas 78229, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Apr 2022, 14 months.

Results were first posted in May 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2021
First posted
Jan 15, 2021
StartActual
Feb 11, 2021
Primary completionActual
Apr 13, 2022
CompletionActual
Apr 20, 2022
Results first posted
May 26, 2023
Last update
Oct 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04711837
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Feb 11, 2021
Primary completion
Apr 13, 2022
Completion
Apr 20, 2022
Results posted
May 26, 2023
Last update
Oct 10, 2025

Study contacts

William Daley, MD
study director · Haisco-USA Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion